GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Applied Biosciences APPB · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Applied Biosciences

Its shares trade under the ticker APPB. It has been listed since 4 November 2015. In the fiscal year to 31 March 2021, it reported revenue of $88,665 and a net loss of $767,220. At that date it held total assets of $1.3m and shareholders' equity of −$291,056.

Applied BioSciences Corp. is a vertically integrated company, which focuses on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics or biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic area. The company is headquartered in New York City, New York. The company went IPO on 2015-11-04. The firm delivers cannabidiol (CBD) products as well as testing and analytics capabilities to its customers. The company sells consumer products, including health and wellness creams, tinctures, edibles, confections, clothing, apparel, and other various branded products. Its various brands include Remedi, Remedi Plus, HerbalPet, Champ Organics and Equine Care. Its products are focused on the medical, bioceutical and pet health industries. The firm's subsidiaries include Applied Products LLC, Trace Analytics, Inc., and API Holdings, LLC, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
4 Nov 2015

Leadership

Pay as last reported

  • Mr. Scott StevensChairman of the Board, since 2019
  • Mr. Chris BridgesPresident, Director, since 2017
  • Mr. John SouthardTreasurer, Secretary
  • Dr. Michael BeaubaireDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Vertically integrated company focusing on synthetic cannabinoid therapeutics
  • Headquartered in New York City with an IPO in 2015
  • Offers CBD products and testing analytics capabilities

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No financial data provided for analysis
  • No details on market share or competitive position

Opportunities

  • Expansion into medical, bioceutical, and pet health industries
  • Growth potential in synthetic cannabinoid therapeutics market
  • Potential for brand diversification with existing brands like Remedi and HerbalPet

Threats

  • Untrusted source description may contain inaccurate information
  • No data on regulatory challenges in pharmaceutical sector
  • No information on competition within the cannabinoid therapeutics market

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.